Idea Development Award – HT942526LCRPIDA
- Pre-proposals due 23 June 2026
- Up to USD$800,000 over 3 years
- Supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering
- promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation
- Applications only in the area of mesothelioma will not be accepted
- New Investigator option available
- Emphasis on innovation and impact.
- preliminary data required (does not need to be derived from lung cancer studies)
- clinical trials not allowed
- relevance to military health strongly encouraged
- must address at least one of the areas of emphasis
- Apply here
- Document – Program Announcement – HT942526LCRPIDA_GG
Translational Research Award – HT942526LCRPTRA
- Pre-proposals due 23 June 2026
- Up to USD$1.35M over 3 years (Funding Level 1) or up to USD$1.85M over 4 years
- Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may include integration of basic science and clinical observations.
- Examples of the types of projects supported include
- Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts
- Late-stage preclinical work leading to/preparing for a clinical trial, eg Investigational New Drug application submission
- Correlative studies associated with an open/ongoing or completed clinical trial
- Projects that develop endpoints for clinical trials
- Applications only in the area of mesothelioma will not be accepted
- preliminary lung cancer relevant data required
- Funding Level 1 – Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts; late-stage pre-clinical work leading to/preparing for a clinical trial; Correlative studies associated with an open/ongoing or completed clinical trial, eg projects that utilize biospecimens from clinical trials to improve clinical management of lung cancer and/or define new areas of research; projects that develop endpoints for clinical trials
- Funding Level 2 – Pilot clinical trials where limited clinical testing (eg small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research
- must address at least one of the areas of emphasis in a way that can lead to or directly effect a breakthrough and have a major impact
- Apply here
- Document – Program Announcement – HT942526LCRPTRA_GG
Patient-Centered Outcomes and Survivorship Award – HT942526LCRPPCOSA
- letters of intent due 18 August 2026
- Up to USD$975,000 over 3 years
- Supports high-risk, high-reward studies that span the spectrum of survivorship and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, and co-morbid conditions.
- preliminary data required
- clinical research allowed
- pilot clinical trials allowed
- animal research not allowed
- inclusion of an advocate who is a lung cancer patient/survivor or caregiver required
- relevance to military health strongly encouraged
- must address at least one of the areas of emphasis in the Health outcomes and Survivorship category
- Apply here
- Document – Program Announcement – HT942526LCRPPCOSA_GG
Areas of Emphasis
- Biology and Etiology
- Understand the molecular mechanisms of initiation and progression of pre-malignancy to lung cancer
- Understand contributors to lung cancer development other than tobacco, including hereditary and sex-specific differences
- Understand the biology of metastatic/oligometastatic disease progression
- Prevention and Risk Reduction
- Identify innovative strategies for prevention and/or interception of lung cancer development
- Identify innovative strategies for the prevention of recurrence or metastases from lung cancer
- Detection, Diagnosis and Surveillance
- Improve and expand approaches to screening and early detection of lung cancer
- Identify strategies for prompt detection and/or characterization of progressive disease
- Treatment and Prognosis
- Identify innovative strategies for the treatment of lung cancer, including overcoming resistance
- Develop or optimize biomarkers to assist with therapeutic decision making
- Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer
- Health Outcomes and Survivorship
- Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on quality of life for patients and families
- Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer
- Reduce differences among high-risk groups and populations
